好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Visual Pathway Structure and Function in Pediatric-onset Multiple Sclerosis (POMS): Are Social Determinants of Health (SDOH) Related?
Multiple Sclerosis
P10 - Poster Session 10 (5:00 PM-6:00 PM)
1-011

To determine the relation of visual function tests and optical coherence tomography (OCT) measures to social determinants of health (SDOH) in pediatric-onset multiple sclerosis (POMS).

Growing evidence in the MS literature demonstrates that SDOH (e.g., socioeconomic status, race, ethnicity) can be associated with adverse clinical outcomes, but less is known about the impact of SDOH among individuals with POMS. Visual function is a fundamental dimension of MS and OCT is an important non-invasive structural marker. Here, we investigate how SDOH relate to OCT and neuro-ophthalmic outcomes in POMS.

This was a cross-sectional study of neuro-ophthalmic clinical measures, OCT, and volumetric MRI measures in patients with POMS at a pediatric MS center.  Patients were included if both a volumetric MRI and a ophthalmologic evaluation had been performed. Self-identified race, ethnicity, and current insurance type were collected. SDOH indicators included having Medicaid insurance or self-identifying as a minoritized race/ethnicity such as non-White race or Hispanic/Latino ethnicity (termed “minority status”).

Among 72 patients (144 eyes), median age was 19 years (range 10-27) with a median disease duration of 4 years (0-16) at time of MRI. Minority status was associated with worse high-contrast visual acuity (p=0.006, generalized estimating equation [GEE] models, accounting for age at diagnosis and adjusting for within-patient inter-eye correlations). Non-white race was associated with reduced ganglion cell layer thickness (p<0.001) and worse visual acuity (p=0.002). Having Medicaid insurance was also associated with worse visual acuity (p=0.005) and worse Ishihara color testing (p=0.01). There were no significant differences between SDOH proxies and the percentage of patients on disease modifying therapies.

Structural and functional visual outcomes may be adversely affected among POMS patients with SDOH proxies of social vulnerability. More work is needed to understand how social risk factors can affect visual outcomes in individuals with POMS and how to optimize therapeutic approaches.

Authors/Disclosures
Anna Sosa
PRESENTER
Anna Sosa has nothing to disclose.
Ruben Jauregui, MD Dr. Jauregui has nothing to disclose.
Ugo Nwigwe Mr. Nwigwe has nothing to disclose.
Kimberly O'Neill, MD Dr. O'Neill has nothing to disclose.
Rachel Kenney Rachel Kenney has received personal compensation for serving as an employee of Optum. Rachel Kenney has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Minton 好色先生 LLC.
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center) Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Steven Galetta, MD, FAAN (NYU Langone Medical Center) Dr. Galetta has nothing to disclose.
Laura J. Balcer, MD, MSCE, FAAN (NYU Grossman School of Medicine) An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.
Scott Grossman, MD (New York University, Langone Health) Dr. Grossman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acuta Pharmaceuticals.